SELLAS Life Sciences Group (SLS) Competitors

$7.04 +0.51 (+7.79%)

As of 12:43 PM Eastern

SLS vs. VKTX, TLX, TWST, OGN, and BEAM

Should you buy SELLAS Life Sciences Group stock or one of its competitors? MarketBeat compares SELLAS Life Sciences Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SELLAS Life Sciences Group include Viking Therapeutics (VKTX), Telix Pharmaceuticals (TLX), Twist Bioscience (TWST), Organon & Co. (OGN), and Beam Therapeutics (BEAM). These companies are all part of the "pharmaceutical products" industry.

How does SELLAS Life Sciences Group compare to Viking Therapeutics?

SELLAS Life Sciences Group (NASDAQ:SLS) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Viking Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.25	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

SELLAS Life Sciences Group's return on equity of -61.95% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-61.95%	-54.48%
Viking Therapeutics	N/A	-71.31%	-65.35%

In the previous week, SELLAS Life Sciences Group had 7 more articles in the media than Viking Therapeutics. MarketBeat recorded 12 mentions for SELLAS Life Sciences Group and 5 mentions for Viking Therapeutics. Viking Therapeutics' average media sentiment score of 1.28 beat SELLAS Life Sciences Group's score of 0.90 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viking Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group presently has a consensus target price of $10.00, suggesting a potential upside of 43.04%. Viking Therapeutics has a consensus target price of $95.50, suggesting a potential upside of 203.77%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.85

SELLAS Life Sciences Group has a beta of 2.24, indicating that its share price is 124% more volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 1.4% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Viking Therapeutics beats SELLAS Life Sciences Group on 8 of the 14 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Telix Pharmaceuticals?

SELLAS Life Sciences Group (NASDAQ:SLS) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Telix Pharmaceuticals has higher revenue and earnings than SELLAS Life Sciences Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.25	N/A
Telix Pharmaceuticals	$803.79M	4.59	-$7.12M	N/A	N/A

Telix Pharmaceuticals' return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-61.95%	-54.48%
Telix Pharmaceuticals	N/A	N/A	N/A

In the previous week, SELLAS Life Sciences Group had 7 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 12 mentions for SELLAS Life Sciences Group and 5 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 1.06 beat SELLAS Life Sciences Group's score of 0.90 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	0 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group currently has a consensus target price of $10.00, suggesting a potential upside of 43.04%. Telix Pharmaceuticals has a consensus target price of $21.13, suggesting a potential upside of 94.36%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Telix Pharmaceuticals is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

SELLAS Life Sciences Group has a beta of 2.24, indicating that its stock price is 124% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market.

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 1.4% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Telix Pharmaceuticals beats SELLAS Life Sciences Group on 9 of the 13 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Twist Bioscience?

SELLAS Life Sciences Group (NASDAQ:SLS) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

SELLAS Life Sciences Group has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Twist Bioscience's return on equity of -26.73% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-61.95%	-54.48%
Twist Bioscience	-19.85%	-26.73%	-19.15%

In the previous week, SELLAS Life Sciences Group and SELLAS Life Sciences Group both had 12 articles in the media. Twist Bioscience's average media sentiment score of 1.07 beat SELLAS Life Sciences Group's score of 0.90 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SELLAS Life Sciences Group	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group currently has a consensus target price of $10.00, suggesting a potential upside of 43.04%. Twist Bioscience has a consensus target price of $56.57, suggesting a potential upside of 4.96%. Given SELLAS Life Sciences Group's higher probable upside, analysts plainly believe SELLAS Life Sciences Group is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

SELLAS Life Sciences Group has a beta of 2.24, indicating that its stock price is 124% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.22, indicating that its stock price is 122% more volatile than the broader market.

SELLAS Life Sciences Group has higher earnings, but lower revenue than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.25	N/A
Twist Bioscience	$376.57M	8.91	-$77.67M	-$1.33	N/A

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 1.4% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 3.1% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

SELLAS Life Sciences Group and Twist Bioscience tied by winning 7 of the 14 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Organon & Co.?

Organon & Co. (NYSE:OGN) and SELLAS Life Sciences Group (NASDAQ:SLS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by company insiders. Comparatively, 1.4% of SELLAS Life Sciences Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, SELLAS Life Sciences Group had 5 more articles in the media than Organon & Co.. MarketBeat recorded 12 mentions for SELLAS Life Sciences Group and 7 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.59 beat SELLAS Life Sciences Group's score of 0.90 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
SELLAS Life Sciences Group	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has a net margin of 3.99% compared to SELLAS Life Sciences Group's net margin of 0.00%. Organon & Co.'s return on equity of 99.95% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
SELLAS Life Sciences Group	N/A	-61.95%	-54.48%

Organon & Co. currently has a consensus target price of $11.40, suggesting a potential downside of 14.70%. SELLAS Life Sciences Group has a consensus target price of $10.00, suggesting a potential upside of 43.04%. Given SELLAS Life Sciences Group's stronger consensus rating and higher possible upside, analysts plainly believe SELLAS Life Sciences Group is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Organon & Co. has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.24, indicating that its share price is 124% more volatile than the broader market.

Organon & Co. has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.56	$187M	$0.93	14.37
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.25	N/A

Summary

Organon & Co. beats SELLAS Life Sciences Group on 10 of the 15 factors compared between the two stocks.

How does SELLAS Life Sciences Group compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and SELLAS Life Sciences Group (NASDAQ:SLS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Beam Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.24, suggesting that its share price is 124% more volatile than the broader market.

Beam Therapeutics currently has a consensus price target of $46.83, indicating a potential upside of 58.03%. SELLAS Life Sciences Group has a consensus price target of $10.00, indicating a potential upside of 43.04%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Beam Therapeutics is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 1.4% of SELLAS Life Sciences Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

SELLAS Life Sciences Group has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.82	-$79.99M	-$0.68	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.25	N/A

In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than Beam Therapeutics. MarketBeat recorded 12 mentions for SELLAS Life Sciences Group and 11 mentions for Beam Therapeutics. SELLAS Life Sciences Group's average media sentiment score of 0.90 beat Beam Therapeutics' score of 0.72 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
SELLAS Life Sciences Group	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
SELLAS Life Sciences Group	N/A	-61.95%	-54.48%

Summary

Beam Therapeutics beats SELLAS Life Sciences Group on 10 of the 16 factors compared between the two stocks.

Get SELLAS Life Sciences Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLS vs. The Competition

Export

Metric	SELLAS Life Sciences Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.30B	$3.42B	$6.31B	$12.44B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-30.63	18.75	21.00	25.62
Price / Sales	N/A	296.19	558.69	75.49
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	15.20	6.77	9.84	6.72
Net Income	-$26.86M	$24.11M	$3.55B	$333.51M
7 Day Performance	41.81%	0.20%	-0.18%	0.32%
1 Month Performance	43.85%	1.11%	1.54%	4.21%
1 Year Performance	362.98%	78.26%	41.14%	36.13%

SELLAS Life Sciences Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLS SELLAS Life Sciences Group	1.5086 of 5 stars	$7.04 +7.8%	$10.00 +42.1%	+363.1%	$1.30B	N/A	N/A	10	News Coverage Earnings Report Options Volume
VKTX Viking Therapeutics	4.0627 of 5 stars	$31.72 +1.2%	$95.50 +201.1%	+14.3%	$3.64B	N/A	N/A	20
TLX Telix Pharmaceuticals	4.6522 of 5 stars	$10.83 +1.4%	$21.13 +95.1%	-37.0%	$3.62B	$803.79M	N/A	1,184	Positive News
TWST Twist Bioscience	1.8444 of 5 stars	$56.21 -1.1%	$56.57 +0.6%	+68.4%	$3.54B	$376.57M	N/A	990	Positive News
OGN Organon & Co.	3.1453 of 5 stars	$13.33 -0.2%	$11.40 -14.4%	+58.1%	$3.51B	$6.16B	14.33	10,000	Positive News Ex-Dividend

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SELLAS Life Sciences Group (SLS) Competitors

SLS vs. VKTX, TLX, TWST, OGN, and BEAM

How does SELLAS Life Sciences Group compare to Viking Therapeutics?

Summary

How does SELLAS Life Sciences Group compare to Telix Pharmaceuticals?

Summary

How does SELLAS Life Sciences Group compare to Twist Bioscience?

Summary

How does SELLAS Life Sciences Group compare to Organon & Co.?

Summary

How does SELLAS Life Sciences Group compare to Beam Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS vs. The Competition

SELLAS Life Sciences Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SELLAS Life Sciences Group (SLS) Competitors

SLS vs. VKTX, TLX, TWST, OGN, and BEAM

How does SELLAS Life Sciences Group compare to Viking Therapeutics?

Which has higher valuation & earnings, SLS or VKTX?

Is SLS or VKTX more profitable?

Does the media favor SLS or VKTX?

Do analysts prefer SLS or VKTX?

Which has more volatility & risk, SLS or VKTX?

Do insiders and institutionals have more ownership in SLS or VKTX?

Summary

How does SELLAS Life Sciences Group compare to Telix Pharmaceuticals?

Which has stronger earnings & valuation, SLS or TLX?

Is SLS or TLX more profitable?

Does the media refer more to SLS or TLX?

Do analysts prefer SLS or TLX?

Which has more risk & volatility, SLS or TLX?

Do institutionals and insiders have more ownership in SLS or TLX?

Summary

How does SELLAS Life Sciences Group compare to Twist Bioscience?

Is SLS or TWST more profitable?

Does the media refer more to SLS or TWST?

Do analysts prefer SLS or TWST?

Which has more risk & volatility, SLS or TWST?

Which has stronger earnings & valuation, SLS or TWST?

Do institutionals and insiders have more ownership in SLS or TWST?

Summary

How does SELLAS Life Sciences Group compare to Organon & Co.?

Do insiders & institutionals hold more shares of OGN or SLS?

Does the media prefer OGN or SLS?

Is OGN or SLS more profitable?

Do analysts recommend OGN or SLS?

Which has more risk & volatility, OGN or SLS?

Which has stronger earnings & valuation, OGN or SLS?

Summary

How does SELLAS Life Sciences Group compare to Beam Therapeutics?

Which has more risk and volatility, BEAM or SLS?

Do analysts rate BEAM or SLS?

Do insiders & institutionals believe in BEAM or SLS?

Which has better valuation and earnings, BEAM or SLS?

Does the media prefer BEAM or SLS?

Is BEAM or SLS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLS vs. The Competition

SELLAS Life Sciences Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools